AU2001241541A1 - Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer - Google Patents

Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer

Info

Publication number
AU2001241541A1
AU2001241541A1 AU2001241541A AU4154101A AU2001241541A1 AU 2001241541 A1 AU2001241541 A1 AU 2001241541A1 AU 2001241541 A AU2001241541 A AU 2001241541A AU 4154101 A AU4154101 A AU 4154101A AU 2001241541 A1 AU2001241541 A1 AU 2001241541A1
Authority
AU
Australia
Prior art keywords
kits
assessment
therapy
prevention
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001241541A
Inventor
Wilson O. Endege
John E. Monahan
Robert Schlegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MILLENNIUM PREDICTIVE MEDICINE Inc
Original Assignee
MILLENNIUM PREDICTIVE MEDICINE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MILLENNIUM PREDICTIVE MEDICINE filed Critical MILLENNIUM PREDICTIVE MEDICINE
Publication of AU2001241541A1 publication Critical patent/AU2001241541A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
AU2001241541A 2000-02-17 2001-02-20 Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer Abandoned AU2001241541A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US18331900P 2000-02-17 2000-02-17
US60183319 2000-02-17
US18986200P 2000-03-16 2000-03-16
US60189862 2000-03-16
US20745400P 2000-05-25 2000-05-25
US60207454 2000-05-25
US21131400P 2000-06-09 2000-06-09
US60211314 2000-06-09
US21900700P 2000-07-18 2000-07-18
US60219007 2000-07-18
US25528100P 2000-12-13 2000-12-13
US60255281 2000-12-13
PCT/US2001/005171 WO2001060860A2 (en) 2000-02-17 2001-02-20 Genes differentially expressed in human prostate cancer and their use

Publications (1)

Publication Number Publication Date
AU2001241541A1 true AU2001241541A1 (en) 2001-08-27

Family

ID=27558741

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001241541A Abandoned AU2001241541A1 (en) 2000-02-17 2001-02-20 Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer

Country Status (3)

Country Link
US (1) US20040259086A1 (en)
AU (1) AU2001241541A1 (en)
WO (1) WO2001060860A2 (en)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045420A1 (en) 1997-04-10 1998-10-15 Diagnocure Inc. Pca3, pca3 genes, and methods of use
US20030170794A1 (en) * 1997-09-18 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20080050836A1 (en) * 1998-05-01 2008-02-28 Isabelle Guyon Biomarkers for screening, predicting, and monitoring benign prostate hyperplasia
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
ES2329851T3 (en) 1998-06-01 2009-12-01 Agensys, Inc. NEW TRANSMEMBRANABLE ANTIGENS EXPRESSED IN HUMAN CANCER AND USING THEMSELVES.
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7339033B2 (en) * 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
US20030190669A1 (en) 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP4495349B2 (en) * 1999-01-28 2010-07-07 ジェン−プローブ・インコーポレーテッド Nucleic acid sequences for detecting cancer genetic markers in biological samples
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
EP1621620A3 (en) * 1999-09-01 2006-05-10 Genetech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
PT1222266E (en) 1999-09-29 2006-07-31 Diagnocure Inc PCA3 MESSENGER RNA IN BENEFICIAL AND MALIGNAL PROSTATE TISSUES
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
US7534417B2 (en) 2000-02-24 2009-05-19 Agensys, Inc. 103P2D6: tissue specific protein highly expressed in various cancers
US7070947B2 (en) 2000-02-29 2006-07-04 Millennium Pharmaceuticals, Inc. Human protein kinase, phosphatase, and protease family members and uses thereof
EP1268762A4 (en) * 2000-03-31 2003-08-27 Nuvelo Inc Novel nucleic acids and polypeptides
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
KR100787073B1 (en) 2000-06-28 2007-12-21 글리코파이, 인크. Methods for producing modified glycoproteins
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
AU2001273452A1 (en) * 2000-07-13 2002-01-30 Millennium Pharmaceuticals, Inc. 47885, a novel human ubiquitin-activating enzyme and uses therefor
ATE416253T1 (en) * 2000-08-21 2008-12-15 Millennium Pharm Inc ATCR-1, A HUMAN ACYL TRANSFERASE AND USES THEREOF
EP1399584A2 (en) * 2000-10-11 2004-03-24 Avalon Pharmaceuticals Cancer-linked genes as targets for chemotherapy
MXPA03003151A (en) * 2000-10-13 2003-08-19 Eos Biotechnology Inc Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer.
AU2002214598A1 (en) * 2000-10-17 2002-04-29 California Institute Of Technology Claspin proteins and methods of use thereof
WO2002040672A2 (en) 2000-11-20 2002-05-23 Diadexus, Inc. Compositions and methods relating to breast specific genes and proteins
WO2002044332A2 (en) * 2000-12-01 2002-06-06 Origene Technologies Inc Prostate polynucleotides and uses
JP2004535765A (en) 2000-12-07 2004-12-02 カイロン コーポレイション Endogenous retrovirus up-regulated in prostate cancer
WO2002060953A2 (en) 2000-12-15 2002-08-08 Agensys, Inc. Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
EP1356049A2 (en) * 2000-12-15 2003-10-29 Millennium Pharmaceuticals, Inc. Human sugar transporter proteins, potassium channel proteins, phospholipid transporter proteins and methods of use thereof
US20090226915A1 (en) 2001-01-24 2009-09-10 Health Discovery Corporation Methods for Screening, Predicting and Monitoring Prostate Cancer
US6989441B2 (en) * 2001-02-15 2006-01-24 Millennium Pharmaceuticals, Inc. 25466, a human transporter family member and uses therefor
AU2002308285A1 (en) * 2001-02-21 2002-09-04 Bayer Aktiengesellschaft Regulation of human phosphatidic acid-preferring phospholipase a1
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
GB0106782D0 (en) 2001-03-19 2001-05-09 Univ The Glasgow Polypeptides, methods and means
US20040006205A1 (en) * 2001-04-03 2004-01-08 Li Li Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002083921A2 (en) * 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
AU2002307250B2 (en) * 2001-04-10 2006-09-14 Agensys, Inc. Nucleic acid and corresponding protein entitled 121P2A3 useful in treatment and detection of cancer
US7309760B2 (en) * 2001-04-17 2007-12-18 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
US7195868B2 (en) * 2001-04-18 2007-03-27 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention, and therapy of human cancers
GB0112453D0 (en) * 2001-05-22 2001-07-11 Pharma Pacific Pty Ltd Interferon-alpha induced gene
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
AU2002322280A1 (en) 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
JP2005505258A (en) 2001-06-21 2005-02-24 イシス・イノベイション・リミテッド ANGE gene in atopy
WO2003018807A1 (en) 2001-08-24 2003-03-06 Hisamitsu Pharmaceutical Co., Inc. Nucleic acids showing difference in expression between hepatoblastoma anc normal liver
AU2002336446B2 (en) 2001-09-06 2008-03-06 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
WO2003024392A2 (en) 2001-09-18 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040038877A1 (en) * 2001-10-02 2004-02-26 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
EP1520032A4 (en) * 2001-11-02 2007-07-18 Pfizer Prod Inc Lung cancer therapeutics and diagnostics
US7226594B2 (en) 2001-11-07 2007-06-05 Agensys, Inc. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
EP1310552B1 (en) 2001-11-09 2007-06-13 Proteologics, Inc. Posh nucleic acids, polypeptides and related methods
US7449548B2 (en) 2001-12-07 2008-11-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
JP4822490B2 (en) * 2001-12-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Endogenous retroviral polypeptides associated with oncogenic transformation
DE60235413D1 (en) 2001-12-07 2010-04-01 Novartis Vaccines & Diagnostic IN PROSTATE CANCER HIGHLY REGULATED ENDOGENIC RETROVIRUS
US20060275747A1 (en) * 2001-12-07 2006-12-07 Hardy Stephen F Endogenous retrovirus up-regulated in prostate cancer
US20030144188A1 (en) * 2002-01-15 2003-07-31 Biaoyang Lin Androgen regulated nucleic acid molecules and encoded proteins
US8008012B2 (en) 2002-01-24 2011-08-30 Health Discovery Corporation Biomarkers downregulated in prostate cancer
JPWO2003068973A1 (en) * 2002-02-13 2005-06-02 暉勝 有馬 DNA sequences and encoded polypeptides useful for the diagnosis of hepatitis
DE10211088A1 (en) * 2002-03-13 2003-09-25 Ugur Sahin Gene products differentially expressed in tumors and their use
FR2837391B1 (en) * 2002-03-22 2007-04-20 Gene Signal REGULATORY GENES OF ANGIOGENESIS, PHARMACEUTICAL PREPARATIONS CONTAINING SAME AND APPLICATIONS THEREOF
US7803906B2 (en) 2002-03-22 2010-09-28 Gene Signal International Sa Composition comprising an angiogenesis related protein
AU2003248528A1 (en) * 2002-05-15 2003-12-02 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
WO2003097801A2 (en) * 2002-05-16 2003-11-27 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
BRPI0311822B8 (en) * 2002-06-06 2021-05-25 Oncotherapy Science Inc pharmaceutical composition for the treatment of cancer
EP2302039A1 (en) * 2002-06-13 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Virus-like particles comprising HML-2 gag polypeptide
US20060189518A1 (en) * 2002-06-26 2006-08-24 Takeda Pharmaceutical Company Limited Preventing/remedies for cancer
DE10230692A1 (en) * 2002-07-08 2004-02-12 Epigenomics Ag Methods and nucleic acids for the analysis of methylation patterns within the DD3 gene
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
AU2002951346A0 (en) * 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
EP1551876B1 (en) 2002-10-16 2011-03-16 Purdue Pharma L.P. Antibodies that bind cell-associated ca 125/0722p and methods of use thereof
EP1558737A4 (en) * 2002-10-18 2008-06-11 Lg Life Sciences Ltd Gene families associated with cancers
EP2322202A3 (en) * 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune diseases
AU2003300815A1 (en) * 2002-12-05 2004-06-30 Incyte Corporation Protein modification and maintenance molecules
US20050282170A1 (en) 2003-02-07 2005-12-22 Diagnocure Inc. Method to detect prostate cancer in a sample
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
WO2005017104A2 (en) * 2003-06-16 2005-02-24 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
EP1636379A2 (en) * 2003-06-26 2006-03-22 Exonhit Therapeutics S.A. Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
EP2311468B1 (en) 2003-08-08 2014-01-15 Perseus Proteomics Inc. Gene overexpressed in cancer
DE10345011A1 (en) * 2003-09-22 2005-04-14 Staub, Eike Use of metarring-binding substances for the diagnosis and treatment of cancer
DE10344799A1 (en) * 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
AU2015201738B2 (en) * 2003-09-26 2016-10-13 Biontech Ag Identification of tumour-associated cell surface antigens for diagnosis and therapy
CN100484568C (en) * 2003-12-11 2009-05-06 中国人民解放军军事医学科学院放射与辐射医学研究所 Antibiosis usage of a family of protein
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US20080199468A1 (en) * 2004-02-24 2008-08-21 Oncotherapy Science, Inc. Method For Diagnosing Colorectal Cancers
WO2005085865A2 (en) * 2004-03-09 2005-09-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with thyroid hormone receptor beta (thrb)
EP1727831A1 (en) * 2004-03-23 2006-12-06 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
ES2443996T3 (en) 2004-04-22 2014-02-21 Agensys, Inc. Antibodies and molecules derived from them that bind to STEAP-1 proteins
WO2005111213A1 (en) * 2004-05-18 2005-11-24 Kurume University Target gene mimitin of myc
WO2006008005A2 (en) * 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 2 (hzf2)
WO2006022689A1 (en) * 2004-08-06 2006-03-02 Applera Corporation Method and compositions for treating diseases targeting cd51
WO2006023598A2 (en) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
US11105808B2 (en) 2004-11-12 2021-08-31 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
US20070250956A1 (en) 2005-01-14 2007-10-25 University Of Guelph Nitrogen-Regulated Sugar Sensing Gene and Protein and Modulation Thereof
MX2007008568A (en) 2005-01-14 2008-01-11 Univ Guelph Nitrogen-regulated sugar sensing gene and protein and modulation thereof.
WO2006086345A2 (en) * 2005-02-07 2006-08-17 The Trustees Of Columbia University In The City Of New York Methods to treat or prevent hormone-resistant prostate cancer using sirna specific for protocadherin-pc, or other inhibitors of protocadherin-pc expression or activity
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
NZ562453A (en) 2005-03-31 2010-04-30 Agensys Inc Antibodies and related molecules that bind to 161P2F10B proteins
US8350009B2 (en) 2005-03-31 2013-01-08 Agensys, Inc. Antibodies and related molecules that bind to 161P2F10B proteins
US20060263788A1 (en) * 2005-05-17 2006-11-23 Ken-Shwo Dai Human kinase interacting protein 2 (KIP2)-related gene variant (KIP2V1) associated with prostate cancer
EP1728799B1 (en) * 2005-06-02 2008-08-20 Bioptik Technology, Inc. Human kinase interacting protein 2 (KIP2)-related gene variant (KIP2V1) associated with prostate cancer
JP5512125B2 (en) 2005-09-12 2014-06-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Recurrent gene fusion in prostate cancer
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20070071755A1 (en) * 2005-09-27 2007-03-29 David Balasundaram Novel nucleolar GTPases and method for controlling proliferation of cells
WO2007041359A2 (en) * 2005-09-29 2007-04-12 The Regents Of The University Of California Compositions and methods relating to cornelia de lange syndrome
US20090269744A1 (en) * 2005-10-28 2009-10-29 Exonhit Therapeutics Sa Cancer detection method
DE102005059242A1 (en) * 2005-12-12 2007-06-14 Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten Molecular markers for tumor diagnosis and therapy
EP1900824A1 (en) * 2006-09-14 2008-03-19 Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts Gene expression signature for the prognosis, diagnosis and therapy of prostate cancer and uses thereof
SI2502938T1 (en) 2006-10-27 2015-05-29 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
WO2008052238A1 (en) * 2006-11-01 2008-05-08 The University Of Sydney Treatment of urological cancer
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
JP5597534B2 (en) 2007-05-16 2014-10-01 ジェネ シグナル インターナショナル エスエー Anti-neoplastic drugs, medicaments, compositions and uses thereof
US9303291B2 (en) 2007-07-06 2016-04-05 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
WO2009140741A1 (en) * 2008-05-23 2009-11-26 The University Of Queensland Agents and methods for diagnosing the presence or risk of prostate cancer
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
DE102008031699A1 (en) 2008-07-04 2010-01-14 Protagen Ag Marker sequences for prostate inflammatory diseases, prostate cancer and their use
CN108359719A (en) 2009-05-26 2018-08-03 奎斯特诊断投资公司 The detection method of gene imbalance
US9938582B2 (en) 2009-09-17 2018-04-10 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2011079191A1 (en) 2009-12-23 2011-06-30 Quest Diagnostics Investments Incorporated Tmprss2 for the diagnosis of prostate disease
KR101510413B1 (en) 2010-02-08 2015-04-08 어젠시스 인코포레이티드 Antibody drug conjugates (adc) that bind to 161p2f10b proteins
PT2621526T (en) 2010-09-29 2018-08-02 Seattle Genetics Inc Antibody drug conjugates (adc) that bind to 191p4d12 proteins
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
EP2487251A1 (en) 2011-02-13 2012-08-15 Protagen AG Marker sequences for the diagnosis of prostate carcinoma and use of same
EP2791359B1 (en) 2011-12-13 2020-01-15 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
EP3435084B1 (en) 2012-08-16 2023-02-22 Decipher Biosciences, Inc. Prostate cancer prognostics using biomarkers
AU2014259759B2 (en) 2013-05-01 2020-06-18 Ionis Pharmaceuticals, Inc. Compositions and methods
WO2015014869A1 (en) * 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
EP2878678A1 (en) * 2013-12-02 2015-06-03 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. RNA-biomarkers for diagnosis of prostate cancer
FR3016638B1 (en) * 2014-01-23 2018-04-13 Centre National De La Recherche Scientifique - Cnrs - NEW METHOD OF DETECTING PROSTATE CANCER
WO2016087430A1 (en) * 2014-12-01 2016-06-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel RNA-biomarker signature for diagnosis of prostate cancer
CN110506127B (en) 2016-08-24 2024-01-12 维拉科特Sd公司 Use of genomic tags to predict responsiveness of prostate cancer patients to post-operative radiation therapy
WO2018067900A1 (en) 2016-10-06 2018-04-12 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
AU2018210695A1 (en) 2017-01-20 2019-08-08 The University Of British Columbia Molecular subtyping, prognosis, and treatment of bladder cancer
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
BR112019018767A2 (en) 2017-04-03 2020-05-05 Hoffmann La Roche antibodies, bispecific antigen binding molecule, one or more isolated polynucleotides, one or more vectors, host cell, method for producing an antibody, pharmaceutical composition, uses, method for treating a disease in an individual and invention
US11078542B2 (en) 2017-05-12 2021-08-03 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070112860A (en) * 1998-07-14 2007-11-27 코릭사 코포레이션 An isolated immnogenic portion of the prostate tumor protein and methods for diagnosis of prostate cancer using the same

Also Published As

Publication number Publication date
WO2001060860A2 (en) 2001-08-23
WO2001060860A3 (en) 2002-06-13
US20040259086A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
AU2001241541A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU2002337657A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
AU2001229340A1 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2074201A (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
AU2002322280A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2001236519A1 (en) Identification, assessment, prevention, and therapy of prostate cancer
AU4592601A (en) Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU7994200A (en) Compositions and methods for therapy and diagnosis of prostate cancer
AU2002324451A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
HUP0203968A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2003302892A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1515982A4 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2003226676A1 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
AUPQ923100A0 (en) Treatment of prostate cancer
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001252945A1 (en) Compositions and methods for therapy and diagnosis of colon cancer
AU7701100A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2001268467A1 (en) Identification of genes and compounds for treatment of cancer
AU2002246519A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer